Roger Perlmutter - Merck President
| MRK Stock | USD 127.00 0.12 0.09% |
President
Dr. Roger M. Perlmutter, M.D. Ph.D. is Executive Vice President and President Merck Research Laboratories of the Company. He is responsible for the Companys global research and development efforts. Dr. Perlmutter was executive vice president and head of RD at Amgen Inc. from January 2001 to February 2012. During his tenure, Dr. Perlmutter oversaw the development and subsequent approval of a number of novel biologic and small molecule medicines in the areas of cancer, endocrinology, hematology, inflammation and osteoporosis. Prior to joining Amgen, he was executive vice president of worldwide basic research and preclinical development at Merck. He joined Merck as a senior vice president in February 1997. Before assuming leadership roles in industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington, where he also served as chairman of the Department of Immunology and was a Howard Hughes Medical Institute investigator. He is a Fellow of the American Academy of Arts and Sciences and an elected Fellow of the American Association for the Advancement of Science since 2013.
| Age | 67 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Address | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 |
| Phone | 908 740 4000 |
| Web | https://www.merck.com |
Merck Management Efficiency
The company has Return on Asset of 0.0264 % which means that on every $100 spent on assets, it made $0.0264 of profit. This is way below average. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.01. The value of Return On Capital Employed is expected to slide to 0.04. At this time, Merck's Non Current Liabilities Total is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 10.8 B this year, although the value of Total Current Liabilities will most likely fall to about 13.3 B.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Adam Dubow | Bristol Myers Squibb | 53 | |
| Samit Hirawat | Bristol Myers Squibb | 52 | |
| Johna Norton | Eli Lilly and | 56 | |
| Jeffrey Stewart | AbbVie Inc | 55 | |
| Frank DAmelio | Pfizer Inc | 66 | |
| Fionnuala Walsh | Eli Lilly and | 56 | |
| David Elkins | Bristol Myers Squibb | 56 | |
| Charles Bancroft | Bristol Myers Squibb | 59 | |
| James Swanson | Johnson Johnson | 58 | |
| Sandra Leung | Bristol Myers Squibb | 60 | |
| Christi Shaw | Eli Lilly and | 51 | |
| Albert Bourla | Pfizer Inc | 59 | |
| Karen Santiago | Bristol Myers Squibb | 50 | |
| Michael Sneed | Johnson Johnson | 60 | |
| David Reese | Amgen Inc | 55 | |
| Jyoti Mehra | Gilead Sciences | 48 | |
| Francis Cuss | Bristol Myers Squibb | 60 | |
| Thomas Lynch | Bristol Myers Squibb | 57 | |
| Kathryn Metcalfe | Bristol Myers Squibb | 50 | |
| Cynthia Patton | Amgen Inc | 56 | |
| Lidia Fonseca | Pfizer Inc | 55 | |
Management Performance
| Return On Equity | 0.009 | ||||
| Return On Asset | 0.0264 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scot Ebbinghaus, VP Development | ||
| Rochelle Lazarus, Independent Director | ||
| Michael Rosenblatt, Executive Vice President Chief Medical Officer | ||
| Paul Rothman, Independent Director | ||
| Mary Coe, Independent Director | ||
| Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer | ||
| Caroline Litchfield, Chief Financial Officer, Executive Vice President | ||
| Mirian GraddickWeir, Executive Vice President - Human Resources | ||
| Jannie Oosthuizen, Lead - Human Health U.S. | ||
| Jennifer Mauer, VP Communications | ||
| Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health | ||
| Gregory Lubiniecki, VP Development | ||
| Michael Klobuchar, Executive Vice President Chief Strategy Officer | ||
| Patricia Russo, Independent Director | ||
| David Williams, Executive Vice President Chief Information Chief Information and Digital Officer | ||
| Franklin Clyburn, President, Human Health, Head of Human Health Commercial and Marketing | ||
| Lisa LeCointeCephas, Senior Vice President Chief Ethics and Compliance Officer | ||
| Robert Davis, Executive Vice President, Global Services, Chief Financial Officer | ||
| Robert Kidder, Independent Director | ||
| Thomas Cech, Independent Director | ||
| William Harrison, Lead Independent Director | ||
| Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources | ||
| Jim Scholefield, Executive Vice President, Chief Information and Digital Officer | ||
| Deepak Khanna, Lead - Human Health International | ||
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
| Gideon Blumenthal, Vice Affairs | ||
| Adam Schechter, President of Global Human Health and Executive VP | ||
| Risa LavizzoMourey, Independent Director | ||
| Thomas Glocer, Lead Independent Director | ||
| Craig Thompson, Independent Director | ||
| Cristal Downing, Executive Vice President, Chief Communications, Public Affairs Officer | ||
| Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary | ||
| Arpa Garay, Lead - Human Health Global Marketing | ||
| Dalton III, Principal Finance | ||
| Christine Seidman, Independent Director | ||
| Wendell Weeks, Independent Director | ||
| Michael Holston, Executive Vice President Chief Ethics and Compliance Officer | ||
| Kathy Warden, Independent Director | ||
| Adele Ambrose, Senior Vice President Chief Communications Officer | ||
| Joseph Romanelli, IR Contact Officer | ||
| Peter Wendell, Independent Director | ||
| John Noseworthy, Independent Director | ||
| Leslie Brun, Lead Independent Director | ||
| Inge Thulin, Independent Director | ||
| Pamela Craig, Independent Director | ||
| Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division | ||
| Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller | ||
| Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories | ||
| Chirfi Guindo, Senior Health | ||
| Joerg Koglin, Vice Development | ||
| Stephen Mayo, Independent Director | ||
| Michael Nally, Executive Vice President, Chief Marketing Officer | ||
| Peter Dannenbaum, Vice Relations | ||
| Clark Golestani, CIO and Executive VP | ||
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
| Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer | ||
| Carlos Represas, Independent Director | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer | ||
| Frank Clyburn, Executive Vice President, Chief Commercial Officer | ||
| Robert JD, President Chairman |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.009 | ||||
| Return On Asset | 0.0264 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.0008 % | ||||
| Current Valuation | 350.57 B | ||||
| Shares Outstanding | 2.53 B | ||||
| Shares Owned By Insiders | 0.04 % | ||||
| Shares Owned By Institutions | 78.59 % | ||||
| Number Of Shares Shorted | 19.59 M | ||||
| Price To Earning | 18.05 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.453 | Dividend Share 2.92 | Earnings Share 0.14 | Revenue Per Share 23.695 | Quarterly Revenue Growth 0.058 |
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.